Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 3.3% – Time to Sell?

Ascentage Pharma Group International (NASDAQ:AAPG)’s stock price dropped 3.3% during trading on Tuesday . The company traded as low as $23.00 and last traded at $23.00. Approximately 2,597 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 63,969 shares. The stock had previously closed at $23.78.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. assumed coverage on shares of Ascentage Pharma Group International in a research note on Thursday, March 27th. They set an “overweight” rating on the stock.

Ascentage Pharma Group International Price Performance

The stock has a 50 day simple moving average of $21.61.

Institutional Trading of Ascentage Pharma Group International

An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC bought a new stake in Ascentage Pharma Group International (NASDAQ:AAPG) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 159,942 shares of the company’s stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned about 0.18% of Ascentage Pharma Group International as of its most recent SEC filing.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.